Search

A new method for the fabrication of flower-like tellurium nanoparticles is reported. It is based on the reduction of tellurite precursor by products generated during decomposition of sulforaphane at elevated temperature in aqueous medium. These species and other organic molecules present in the reaction mixture are being adsorbed on the surface of tellurium nuclei and govern further tellurium growth in the form of nanoflowers. The obtained particles have been characterized by a range of physicochemical techniques. It was shown that the average size of the nanoflower particles is ca. 112 nm, and they are composed of smaller domains which are ca. 30 nm in diameter. The domains are crystalline and consist of trigonal tellurium as shown by x-ray diffraction, Raman spectroscopy and high resolution transmission electron microscopy. The tellurium nanoflowers were examined from the perspective of their potential anticancer activity. The in vitro cell viability studies were conducted on breast cancer (MDA-MB-231, MCF-7) and normal cell lines (MCF-10A) employing MTT and CVS assays. It was shown, that the nanoflowers exhibit considerable cytotoxicity against cancer cells which is ca. 3–7 times higher than that observed for reference normal cells. The preliminary in vivo investigations on rats revealed that the nanoflowers accumulate predominantly in pancreas after intraperitoneal administration, without observable negative behavioral effects. [ABSTRACT FROM AUTHOR]

Sulforaphane-modified selenium nanoparticles can be prepared in a simple aqueous-phase redox reaction through reduction of selenite with ascorbic acid. The sulforaphane molecules present in the reaction mixture adsorb on the nanoparticle surface, forming an adlayer. The resulting conjugate was examined with several physicochemical techniques, including microscopy, spectroscopy, x-ray diffraction, dynamic light scattering and zeta potential measurements. As shown in in vivo investigations on rats, the nanomaterial administered intraperitoneally is eliminated mainly in urine (and, to a lesser extent, in feces); however, it is also retained in the body. The modified nanoparticles mainly accumulate in the liver, but the basic parameters of blood and urine remain within normal limits. The sulforaphane-conjugated nanoparticles reveal considerable anticancer action, as demonstrated on several cancer cell cultures in vitro. This finding is due to the synergistic effect of elemental selenium and sulforaphane molecules assembled in one nanostructure (conjugate). On the other hand, the cytotoxic action on normal cells is relatively low. The high antitumor activity and selectivity of the conjugate with respect to diseased and healthy cells is extremely promising from the point of view of cancer treatment. [ABSTRACT FROM AUTHOR]